Uremic toxin lanthionine interferes with VEGFA, intracellular calcium and PI3K/AKT/mTOR signaling pathway in A-498 clear cell renal carcinoma

Chronic kidney disease is a condition where the body's filtration system slowly loses its ability to clean the blood. As this function declines, a variety of waste products that the kidneys normally remove begin to build up in the bloodstream. These substances, known as uremic toxins, are not just harmless byproducts; they circulate throughout the body and can damage blood vessels, the heart, and other organs. For decades, scientists have known that people with kidney disease face a higher risk of developing cancer, particularly cancers of the kidney itself. However, the exact mechanism connecting the accumulation of these toxins to the growth of tumors has remained a mystery. Researchers have long suspected that the toxic environment created by failing kidneys might directly encourage cancer cells to become more aggressive, but identifying the specific culprit among the many waste products has been difficult.

A new study has turned its attention to a specific waste product called lanthionine. This substance is a sulfur-containing molecule that naturally accumulates in the blood of patients with chronic kidney disease. The researchers wanted to see if lanthionine, at the levels found in sick patients, could directly influence the behavior of kidney cancer cells. To do this, they used two types of human cells in the laboratory: A-498 cells, which are a well-known line of clear cell renal carcinoma (the most common type of kidney cancer), and HEK293 cells, which are healthy, non-cancerous kidney cells. By treating both cell types with lanthionine, the team could observe whether the toxin acted as a general irritant or if it specifically targeted the cancer cells to make them more dangerous.

The results showed a clear difference between the two cell types. When the healthy kidney cells were exposed to lanthionine, they behaved normally, showing no significant changes in their movement or survival. In contrast, the cancer cells reacted strongly. When the researchers treated the cancer cells with lanthionine, the cells began to move and invade surrounding spaces much faster than usual. In a test designed to measure how quickly cells could close a gap, the cancer cells treated with the toxin covered the space in just nine hours, whereas the untreated cells took much longer. Similarly, when the cells were placed in a barrier designed to test their ability to invade through a membrane, the lanthionine-treated cancer cells pushed through with much greater ease. The toxin did not just make the cells move; it also helped them survive and multiply, suggesting that lanthionine acts as a specific accelerator for kidney cancer aggression.

To understand how this happened, the team looked inside the cells to see what signals were being sent. They discovered that lanthionine triggered a rise in calcium levels within the cancer cells. Calcium acts as a universal messenger inside cells, often telling them to grow or move. In the cancer cells, this calcium signal was strong and rapid, but it was completely absent in the healthy cells. The researchers then traced this signal to a specific protein called VEGFA. This protein is famous for helping tumors build new blood vessels, but it also plays a role in telling cancer cells to migrate and invade. The study found that lanthionine caused the cancer cells to produce much more of this VEGFA protein. When the researchers blocked the production of VEGFA in the cancer cells, the toxin lost its power; the cells no longer moved faster, did not invade, and did not show the spike in calcium levels. This proved that VEGFA is the essential link that allows lanthionine to drive the cancer forward.

The investigation went deeper, revealing that this VEGFA signal activated a chain of internal commands known as the PI3K/AKT/mTOR pathway. This pathway is a major control center for cell growth and survival, and its overactivity is a hallmark of many aggressive cancers. In the cancer cells exposed to lanthionine, this pathway was switched on, further fueling the cells' ability to spread. The study also noted that the toxin influenced other factors related to how cells respond to low oxygen, which is a common stressor in tumors. However, the most critical finding was the dependency on VEGFA. Without it, the chain reaction caused by the toxin stopped. The researchers also checked large public databases of human tumor samples and confirmed that VEGFA is indeed highly expressed in kidney cancer compared to normal tissue, reinforcing the relevance of their laboratory findings to real human disease.

This work provides the first experimental evidence that lanthionine is not just a passive marker of kidney failure but an active participant in the progression of kidney cancer. It suggests that the toxic environment of chronic kidney disease can directly stimulate cancer cells to become more invasive and resistant through a specific molecular pathway. While this study was conducted in a laboratory setting and does not yet prove that lowering lanthionine levels in patients will stop cancer, it identifies a clear mechanism that connects kidney dysfunction to tumor growth. The findings highlight a potential new target for understanding why kidney disease and cancer often occur together, and they point toward the possibility that monitoring or managing specific uremic toxins could one day help in the fight against kidney cancer.